Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -30.18% | 65.07% | 50.93% | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -54.36% | -58.39% | -- |
| Total Other Non-Cash Items | -- | -77.74% | 85.43% | -88.83% | -- |
| Change in Net Operating Assets | -- | 55.28% | -369.87% | -83.41% | -- |
| Cash from Operations | 25.53% | -102.83% | 59.98% | -293.60% | 49.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -527.95% | -129.57% | -- |
| Cash from Investing | -446.71% | -- | -527.95% | -129.57% | 823.14% |
| Total Debt Issued | -- | 57.89% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -353.64% | -354.55% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 127.22% | 57.89% | 3,794.00% | 854.39% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,081.96% | -270.84% | 114.18% | -94.14% | 100.84% |